Search

Your search keyword '"Sezary Syndrome"' showing total 141 results

Search Constraints

Start Over You searched for: Descriptor "Sezary Syndrome" Remove constraint Descriptor: "Sezary Syndrome" Journal european journal of cancer Remove constraint Journal: european journal of cancer
141 results on '"Sezary Syndrome"'

Search Results

1. Radiotherapy in cutaneous lymphomas: Recommendations from the EORTC cutaneous lymphoma tumour group.

6. A-214 Evaluation of Sézary cell marker expression and cell death behavior upon in vitro treatment by flow cytometry in Sézary Syndrome patients.

7. A-167 Durable disease control with low-dose total skin electron beam therapy combined with maintenance treatment for patients with erythrodermic mycosis fungoides and Sézary syndrome.

8. A-181 Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome.

9. A-201 Patient-reported symptoms and HRQL of MF and SS patients receiving mogamulizumab over 24 weeks: interim results from the PROSPER study.

18. A-298 RESMAIN: Results of a multicenter, randomized, double blind, placebo-controlled trial to evaluate RESminostat for MAINtenance treatment in advanced stage Mycosis fungoides or Sézary syndrome.

20. A-200 Mogamulizumab in patients with mycosis fungoides or Sézary syndrome: Update on the German non-interventional MINT study.

21. A-122 Lacutamab in Patients with Relapsed and Refractory Sézary Syndrome: Results from the TELLOMAK Phase 2 Trial.

26. A-175 Toward patient-tailored immunotherapy: targeting the TCR idiotype of clonal Sézary lymphomas.

28. Maintenance therapy in patients with mycosis fungoides or Sézary syndrome: A neglected topic.

29. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023.

30. P-205 - Toxic epidermal necrolysis possibly associated with mogamulizumab in a patient with Sézary syndrome.

32. P-194 - Real world evidence: assessing the clinical efficacy of mogamulizumab in mycosis fungoides and Sézary syndrome using time to next treatment.

33. P-191 - Allogeneic hematopoietic stem cell transplantation in patients with advanced mycosis fungoides and Sézary syndrome: 2023 update of the Milan experience.

34. P-184 - Health-related quality of life (HRQL) in cutaneous T-cell lymphoma: burden of disease and patient characteristics from a post-hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome.

35. P-175 - Progressive peripheral polyneuropathy in a patient with Sézary syndrome.

36. P-173 - A real-world international observational study of mogamulizumab in adult patients with mycosis fungoides and Sézary syndrome (PROSPER study NCT05455931).

39. P-169 - Real-world effectiveness of mogamulizumab in patients with Sézary syndrome or mycosis fungoides in Spain and Portugal: The MIBERIC study.

41. O-151 - Non-myeloablative allogeneic stem cell transplantation using TSEBT, TLI and ATG for mycosis fungoides and Sézary syndrome: results from a large single centre cohort.

42. O-152 - Role of total skin electron beam radiotherapy at relapse after allogeneic transplant in mycosis fungoides and Sézary syndrome.

44. O-143 - RESMAIN: results of a multicenter, randomized, double blind, placebocontrolled trial to evaluate resminostat for maintenance treatment in advanced stage mycosis fungoides or Sézary syndrome.

45. O-146 - Efficacy and tolerability of mogamulizumab in patients with mycosis fungoides or Sézary syndrome: retrospective and real-world data from centres of the French Study Group of Cutaneous Lymphoma.

46. O-145 - Mogamulizumab in patients with mycosis fungoides or Sézary syndrome: interim analysis of the German non-interventional MINT study.

47. O-137 - Oncogenic drivers in NF-kappaB pathway-related elements provide candidate targets for future targeted therapies in Sézary syndrome.

Catalog

Books, media, physical & digital resources